MARKET

TOVX

TOVX

THERIVA BIOLOGICS INC
AMEX
0.2469
+0.0059
+2.45%
Opening 12:54 01/06 EST
OPEN
0.2318
PREV CLOSE
0.2410
HIGH
0.2523
LOW
0.2300
VOLUME
2.27M
TURNOVER
--
52 WEEK HIGH
2.030
52 WEEK LOW
0.1651
MARKET CAP
8.33M
P/E (TTM)
-0.0446
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TOVX last week (1229-0102)?
Weekly Report · 1d ago
Why Is Theriva Biologics Stock Gaining Monday?
Benzinga · 12/29/2025 16:41
Theriva Biologics Gains EMA Backing for VCN-01 Phase 3
TipRanks · 12/29/2025 13:33
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design
TipRanks · 12/29/2025 13:05
Weekly Report: what happened at TOVX last week (1222-1226)?
Weekly Report · 12/29/2025 09:53
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Barchart · 12/29/2025 07:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 12/23/2025 21:05
Weekly Report: what happened at TOVX last week (1215-1219)?
Weekly Report · 12/22/2025 09:53
More
About TOVX
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Webull offers Theriva Biologics Inc stock information, including AMEX: TOVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TOVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TOVX stock methods without spending real money on the virtual paper trading platform.